Patients with IBD and cancer history were exposed to anti-TNF inhibitors, vedolizumab and ustekinumab were tested and there was no increase in recurrent risk for cancer in either vedolizumab and ustekinumab after adjusting for age, IBD subtype, smoking, cancer stage. Here, TNF is linked to cancer.